

บรรณานุกรม (Bibliography)

1. Palm W, de Lange T. How shelterin protects Mammalian telomeres. *Annu Rev Genet.* 2008;42:301.
2. Watson JD. Origin of concatemeric T7 DNA. *Nat New Biol.* 1972;239:197.
3. Olonikov AM. A theory of marginotomy. *J. Theor. Biol.* 1973;41:181.
4. Sfeir AJ, Chai W, Shay JW, Wright WE. Telomere-end processing the terminal nucleotides of human chromosomes. *Mol Cell.* 2005;18:147.
5. Ju Z, Lenhard Rudolph K. Telomere dysfunction and stem cell ageing. *Biochimie.* 2008;90:24.
6. Harley CB., Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. *Nature* 1990;345:458.
7. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. *Proc Natl Acad Sci U S A.* 1992;89:10114.
8. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. *Science* 1998;279:349.
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994;266:2011.
10. Jiang XR, Jimenez G, Chang E, et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. *Nat Genet.* 1999;21:111.
11. Fleisig HB, Wong JM. Telomerase as a clinical target: current strategies and potential applications. *Exp Gerontol.* 2007;42:102.
12. Tomás-Loba A, Flores I, Fernández-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borrás C, Matheu A, Klatt P, Flores JM, Viña J, Serrano M, Blasco MA. Telomerase reverse transcriptase delays aging in cancer-resistant mice. *Cell.* 2008;135:609.
13. de Magalhães JP, Toussaint O. Telomeres and telomerase: a modern fountain of youth? *Rejuvenation Res.* 2004;7:126.
14. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. *Science.* 2007 ;315:1850.
15. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. *Cell.* 2008;132:945.

16. Bianchi A, Shore D. How telomerase reaches its end: mechanism of telomerase regulation by the telomeric complex. *Mol Cell*. 2008 ;31:153.
17. Lodish et al. *Molecular Cell Biology*, 5th edition. W.H. Freeman and Company, New York, 2004. P.435-436.
18. Tesmer VM, Ford LP, Holt SE, Frank BC, Yi X, Aisner DL, Ouellette M, Shay JW, Wright WE. Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro. *Mol Cell Biol*. 1999;19:6207.
19. Wen J, Cong YS, Bacchetti S. Reconstitution of wild-type or mutant telomerase activity in telomerase-negative immortal human cells. *Hum Mol Genet*. 1998;7:1137.
20. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. *Microbiol Mol Biol Rev*. 2002;66:407.
21. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. *Oncogene*. 2002;21:541.
22. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). *Nucleic Acids Res*. 2000;28:669.
23. Deng WG, Jayachandran G, Wu G, Xu K, Roth JA, Ji L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. *J Biol Chem*. 2007;282:26460.
24. Cairney CJ, Keith WN. Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. *Biochimie*. 2008;90:13.
25. Parkinson EK, Minty F. Anticancer therapy targeting telomeres and telomerase: current status. *BioDrugs*. 2007;21:375.
26. Harley CB. Telomerase and cancer therapeutics. *Nat Rev Cancer*. 2008;8:167.
27. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. *Br J Cancer*. 2008;98:677.
28. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. *Mol Cell Biol*. 1996;16:53.
29. Pascolo E, Wenz C, Lingner J, Huel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. *J Biol Chem*. 2002;277:15566.
30. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. *Breast Cancer Res Treat*. 2006;96:73.

31. Djojosebroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. *Hepatology*. 2005;42:1127.
32. Yeo M, Rha SY, Jeung HC, Hu SX, Yang SH, Kim YS, An SW, Chung HC. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. *Int J Cancer*. 2005;114:484.
33. Nosrati M, Li S, Bagheri S, Ginzinger D, Blackburn EH, Debs RJ, Kashani-Sabet M. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. *Clin Cancer Res*. 2004;10:4983.
34. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephens KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. *Clin Cancer Res*. 2004;10:828.
35. Pennarun G, Granotier C, Gauthier LR, Gomez D, Hoffschir F, Mandine E, Riou JF, Mergny JL, Mailliet P, Boussin FD. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. *Oncogene* 2005;24:2917.
36. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ, Double JA, Neidle S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. *Cancer Res*. 2005;65:1489.
37. Sumi M, Tauchi T, Sashida G, Nakajima A, Gotoh A, Shin-Ya K, Ohyashiki JH, Ohyashiki K. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. *Int. J. Oncol*. 2004;24:1481.
38. Keppler BR, Jarstfer MB. Inhibition of telomerase activity by preventing proper assemblage. *Biochemistry*. 2004;43:334.
39. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. *Oncogene*. 2002;21:8020.
40. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T. Telomerase-specific replication-selective virotherapy for human cancer. *Clin Cancer Res*. 2004;10:285.
41. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. *Cancer Gene Ther*. 2004;11:174.

42. Kang SS, Lim SE. Growth and telomerase inhibition of SK-MEL 28 melanoma cell line by a plant flavonoid, apigenin. *J Biochem Mol Biol.* 1988;31:339.
43. Chakraborty S, Ghosh U, Bhattacharyya N, Bhattacharya RK, Roy M. Inhibition of telomerase activity in U937 human monocytic leukemia cells by Compound K, a ginseng saponin metabolite. *Mutat Res.* 2006;596:81.
44. Kang KA, LeeKH, Chae S, Kim JK, Seo JY, Ham YH, Lee KH, Kim BJ, Kim HS, Kim DH, Hyun JW. Inhibition of telomerase activity in U937 human monocytic leukemia cells by Compound K, a ginseng saponin metabolite. *Biotech Bioproc Engineer.* 2006;11:7.
45. Giridharan P, Somasundaram ST, Perumal K, Vishwakarma RA, Karthikeyan NP, Velmurugan R, Balakrishnan A. Novel substituted methylenedioxy lignan suppresses proliferation of cancer cells by inhibiting telomerase and activation of c-myc and caspases leading to apoptosis. *Br J Cancer.* 2002;87:98.
46. Lyu SY, Choi SH, Park WB. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. *Arch Pharm Res.* 2002;25:93.
47. Choi SH, Lyu SY, Park WB. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. *Arch Pharm Res.* 2004;27:68.
48. Eitsuka T, Nakagawa K, Igarashi M, Miyazawa T. Telomerase inhibition by sulfoquinovosyl diacylglycerol from edible purple laver (*Porphyra yezoensis*). *Cancer Lett.* 2004;212:15.
49. Park DI, Lee JH, Moon SK, Kim CH, Lee YT, Cheong J, Choi BT, Choi YH. Induction of apoptosis and inhibition of telomerase activity by aqueous extract from *Platycodon grandiflorum* in human lung carcinoma cells. *Pharmacol Res.* 2005;51:437.
50. Singh RK, Mishra SN, Malik M, Bakshi CS, Chittalangia RK, Dwivedi SK, Rawat AK, Garg SK, Butchaiah G. (2002). Development of an In Vitro assay system for screening of anticancer plants for anti-telomerase activity. *Physio Mol Biol Plants.* 2002;8:125.
51. Chen XF, Gu ZL, Yang HH, Liang ZQ, Zhu M, Chen BG. Induction of apoptosis and inhibition of telomerase activity by extract of *Fagopyrum cymosum*(Fr4) in human leukemia HL-60 cells. *Chinese Pharmacol Bull.* 2006;22:836.
52. Guo QL, Lin SS, You QD, Gu HY, Yu J, Zhao L, Qi Q, Liang F, Tan Z, Wang X. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. *Life Sci.* 2006;78:1238.
53. Huang PR, Yeh YM, Wang TC. Potent inhibition of human telomerase by helenalin. *Cancer Lett.* 2005;227:169.



54. Menichincheri M, Ballinari D, Bargiotti A, Bonomini L, Ceccarelli W, D'Alessio R, Fretta A, Moll J, Polucci P, Soncini C, Tibolla M, Trosset JY, Vanotti E. Catecholic flavonoids acting as telomerase inhibitors. *J Med Chem.* 2004;47:6466.
55. Zhang F, Jia Z, Deng Z, Wei Y, Zheng R, Yu L. In vitro modulation of telomerase activity, telomere length and cell cycle in MKN45 cells by verbascoside. *Planta Med.* 2002;68:115.
56. De Cian A, Cristofari G, Reichenbach P, De Lemos E, Monchaud D, Teulade-Fichou MP, Shin-Ya K, Lacroix L, Lingner J, Mergny JL. Reevaluation of telomerase inhibition by quadruplex ligands and their mechanisms of action. *Proc Natl Acad Sci U S A.* 2007;104:17347.
57. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. *Science.* 1994;266:2011.
58. Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA, Kelland LR, Neidle S. 2,7-disubstituted amidofluorenone derivatives as inhibitors of human telomerase. *J Med Chem* 1999;42:2679
59. Szatmari I, Aradi J. Telomeric repeat amplification, without shortening or lengthening of the telomerase products: a method to analyze the processivity of telomerase enzyme. *Nucleic Acids Res.* 2001;29:E3.
60. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat Protoc.* 2006;1:1112.
61. Tuntiwechapikul W, Taka T, Béthencourt M, Makonkawkeyoon L, Randall Lee T. The influence of pH on the G-quadruplex binding selectivity of perylene derivatives. *Bioorg Med Chem Lett.* 2006;16:4120.
62. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ, Ségal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. *J Cell Sci.* 2006;119:2797.

